Segment Data (Tables)

9 Months Ended

Jun. 30, 2022

Segment Reporting [Abstract]

Revenue from External Customers by Geographic Area

Revenues by segment, organizational unit and geographical areas for the three and nine-month periods are detailed below. The Company has no material intersegment revenues.

	Three Months Ended June 30,
(Millions of dollars)	2022						2021
	United States		International		Total		United States		International		Total
Medical
Medication Delivery Solutions (a)	$	621	$	439	$	1,061	$	562	$	456	$	1,019
Medication Management Solutions	463		144		607		459		139		597
Pharmaceutical Systems (a)	135		388		523		112		363		475
Total segment revenues	$	1,219	$	971	$	2,191	$	1,133	$	958	$	2,091
Life Sciences
Integrated Diagnostic Solutions	$	499	$	461	$	961	$	435	$	682	$	1,117
Biosciences	147		201		348		124		192		316
Total segment revenues	$	646	$	663	$	1,309	$	559	$	874	$	1,433
Interventional
Surgery	$	274	$	77	$	352	$	267	$	69	$	336
Peripheral Intervention	255		208		463		238		198		436
Urology and Critical Care	248		79		326		227		83		310
Total segment revenues	$	777	$	364	$	1,142	$	732	$	350	$	1,082
Total Company revenues from continuing operations	$	2,643	$	1,998	$	4,641	$	2,424	$	2,182	$	4,607

(a)Certain prior-period amounts were recast to reflect former intercompany transactions with Embecta.

	Nine Months Ended June 30,
(Millions of dollars)	2022						2021
	United States		International		Total		United States		International		Total
Medical
Medication Delivery Solutions (a)	$	1,831	$	1,375	$	3,207	$	1,665	$	1,382	$	3,046
Medication Management Solutions	1,408		430		1,838		1,376		417		1,793
Pharmaceutical Systems (a)	363		1,057		1,420		292		984		1,276
Total segment revenues	$	3,602	$	2,863	$	6,465	$	3,333	$	2,783	$	6,116
Life Sciences
Integrated Diagnostic Solutions	$	1,732	$	1,524	$	3,255	$	1,904	$	2,141	$	4,045
Biosciences	405		617		1,022		365		588		953
Total segment revenues	$	2,136	$	2,140	$	4,277	$	2,269	$	2,729	$	4,998
Interventional
Surgery	$	824	$	229	$	1,053	$	757	$	203	$	960
Peripheral Intervention	712		615		1,327		692		590		1,282
Urology and Critical Care	740		247		987		672		255		926
Total segment revenues	$	2,276	$	1,091	$	3,367	$	2,120	$	1,047	$	3,168
Total Company revenues from continuing operations	$	8,014	$	6,095	$	14,109	$	7,722	$	6,560	$	14,282

(a)Certain prior-period amounts were recast to reflect former intercompany transactions with Embecta.

Financial Information for Company's Segments

Segment income for the three and nine-month periods was as follows:

	Three Months Ended June 30,				Nine Months Ended June 30,
(Millions of dollars)	2022		2021		2022		2021
Income from Continuing Operations Before Income Taxes
Medical (a)	$	573	$	486	$	1,587	$	1,474
Life Sciences	414		432		1,366		1,953
Interventional	293		214		826		725
Total Segment Operating Income	1,280		1,132		3,778		4,152
Unallocated acquisition-related integration and restructuring expense	(36)		(24)		(99)		(121)
Net interest expense	(94)		(113)		(285)		(351)
Other unallocated items (b)	(728)		(618)		(1,932)		(2,141)
Total Income from Continuing Operations Before Income Taxes	$	421	$	378	$	1,463	$	1,541

(a)The amount for the nine months ended June 30, 2022 includes a non-cash asset impairment charge of $54 million recorded to Cost of products sold in the Medical segment.

(b)Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense. The amount for the nine months ended June 30, 2021 also included pre-tax charges of $296 million recorded to Other operating expense (income), net related to certain product liability matters, including the related legal defense costs, which are further discussed in Note 5.